Structure-Based Design and Synthesis of Fluorescent PPAR.ALPHA./.DELTA. Co-agonist and Its Application as a Probe for Fluorescent Polarization Assay of PPAR.DELTA. Ligands-Reference-Cited by-同舟云学术

Structure-Based Design and Synthesis of Fluorescent PPAR.ALPHA./.DELTA. Co-agonist and Its Application as a Probe for Fluorescent Polarization Assay of PPAR.DELTA. Ligands

Published:2008 Issue:9 Volume:56 Page:1357-1359
ISSN:0009-2363
Container-title:Chemical and Pharmaceutical Bulletin
language:en
Short-container-title:CHEMICAL & PHARMACEUTICAL BULLETIN

Author:

Araya Yoko¹,Kasuga Jun-ichi¹,Toyota Kenji²,Hirakawa Yuko²,Oyama Takuji²,Makishima Makoto³,Morikawa Kosuke²,Hashimoto Yuichi¹,Miyachi Hiroyuki¹

Affiliation:

1. Institute of Molecular and Cellular Biosciences, University of Tokyo

2. The Takara-Bio Endowed Division, Institute for Protein Research, Osaka University

3. School of Medicine, Nihon University

Publisher

Pharmaceutical Society of Japan

Subject

Drug Discovery,General Chemistry,General Medicine

Link

http://www.jstage.jst.go.jp/article/cpb/56/9/56_9_1357/_pdf

Reference13 articles.

1. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

2. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.

3. The PPARs: From Orphan Receptors to Drug Discovery

4. Synthesis of a high-affinity Fluorescent PPARγ ligand for high-throughput fluorescence polarization assays

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attempt to Create a Drug for Treatment of Fibrotic Diseases Based on the Non-genomic Action of Nuclear Receptors;YAKUGAKU ZASSHI;2022-12-01

2. Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR)α Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method;Biological and Pharmaceutical Bulletin;2021-09-01

3. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors;International Journal of Molecular Sciences;2021-08-26

4. Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists;Bioorganic & Medicinal Chemistry Letters;2019-08

5. An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands;European Journal of Medicinal Chemistry;2019-08